Chronic stress is a risk factor for many psychopathological conditions, including depression and anxiety disorders. Cognitive impairments associated with prefrontal cortical dysfunction are a major component of such illnesses. Using an attentional set-shifting test (AST), we have previously shown that elevating noradrenergic activity in rat medial prefrontal cortex (mPFC) can facilitate cognitive set-shifting, and that chronic unpredictable stress (CUS) caused set-shifting deficits. It is not known, however, if noradrenergic modulatory function is compromised by chronic stress, perhaps contributing to the stress-induced cognitive deficit. Thus, the first study investigated whether acutely elevating noradrenergic activity in mPFC still enhances cognitive function after chronic stress. As previously demonstrated, CUS impaired cognitive setshifting on the AST. This deficit was abolished by acute systemic administration of the α 2 -adrenergic autoreceptor antagonist, atipamezole. Microdialysis revealed no differences in extracellular norepinephrine (NE) levels in mPFC of CUS-exposed and unstressed control rats at baseline or during behavioral testing, and comparable increases after atipamezole. In the second experiment, rats were treated chronically with the selective NE reuptake blocker, desipramine, during the CUS treatment through behavioral testing. Again, CUS impaired cognitive set-shifting in vehicle-treated rats, and chronic desipramine treatment prevented such deficits. Acute blockade of post-synaptic α 1 -adrenergic receptors in mPFC prior to testing blocked the beneficial effect of desipramine on cognitive set-shifting. These results suggest that desipramine restores cognitive setshifting capability that has been compromised by chronic stress by activating α 1 -adrenergic receptors in the mPFC. Thus, noradrenergic modulatory capability in mPFC remains intact after CUS, and this represents one possible substrate by which antidepressants may exert their beneficial effects in the treatment of depression.
Introduction
Cognitive impairments associated with prefrontal cortical dysfunction are major components of depression, anxiety disorders and other stress-related psychiatric illnesses (Anisman and Matheson, 2005; Beck, 1976; Beck et al., 1987; Fossati et al., 1999) . The medial prefrontal cortex (mPFC) is particularly important in cognitive setshifting and flexibility, i.e., using feedback from the environment to modify established behavioral patterns in an appropriate manner (Dalley et al., 2004; Ragozzino et al., 1999) . Depressed patients exhibit cognitive flexibility deficits and mPFC hypoactivity (Austin et al., 2001; Beats et al., 1996; Davidson et al., 2002; Rogers et al., 2004) . The attentional set-shifting test (AST) was developed to assess such prefrontal cortical executive capabilities in rats (Birrell and Brown, 2000) . Lesions of rat mPFC specifically impaired cognitive set-shifting on the AST, confirming a function analogous to that of mPFC in humans and non-human primates (Dalley et al., 2004; Dias et al., 1996; Owen et al., 1991; Ragozzino et al., 1999) . The brain noradrenergic (NA) system modulates cognitive function in contexts such as arousal, attention, learning and memory (Berridge et al., 1993; Cole and Robbins, 1992; Devauges and Sara, 1990) . We have previously shown that enhancing NA tone by acute systemic administration of the α 2 -adrenergic autoreceptor antagonist, atipamezole, can improve cognitive set-shifting on the AST, and that this effect was blocked by microinjections of the α 1 -adrenergic receptor antagonist, benoxathian, directly into mPFC (Lapiz and Morilak, 2006) . Norepinephrine (NE) also plays an important role in the physiological and behavioral responses to stress (Aston-Jones et al., 1991; Morilak et al., 2005) . Thus, dysregulation of NE has been
